- Home
- NRXP vs QTRX Comparison
NRXP vs QTRX Comparison
Compare NRXP & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | QTRX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 160.0M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRXP | QTRX |
|---|---|---|
| Price | $3.24 | $2.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $38.25 | $6.00 |
| AVG Volume (30 Days) | ★ 1.1M | 742.3K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,225,000.00 | ★ $37,632,000.00 |
| Revenue This Year | $2,547.84 | $25.49 |
| Revenue Next Year | $1,591.73 | $10.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $1.65 | $2.15 |
| 52 Week High | $5.06 | $8.77 |
Technical Indicators
Market Signals| Indicator | NRXP | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 36.05 |
| Support Level | $2.88 | $2.40 |
| Resistance Level | $3.33 | $3.85 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 30.83 | 24.34 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.